Health TidingsNYB.AI Featured in NVIDIA GTC Taiwan 2026 Opening Showcase, Marking Milesto... NYB.AI Featured in NVIDIA GTC Taiwan 2026 Opening Showcase, Marking Milesto... Read Post »
Health TidingsStructure Reports Up to 16.2% Weight Loss With Oral GLP-1 Aleniglipron Structure Reports Up to 16.2% Weight Loss With Oral GLP-1 Aleniglipron Read Post »
Health TidingsVertex Reports Strong ALYFTREK Results in Young Children With Cystic Fibros... Vertex Reports Strong ALYFTREK Results in Young Children With Cystic Fibros... Read Post »
Health TidingsTeva Reports Quality-of-Life Benefits With AUSTEDO in HD Chorea Teva Reports Quality-of-Life Benefits With AUSTEDO in HD Chorea Read Post »
Health TidingsSouth Africa Rolls Out Lenacapavir to Prevent HIV South Africa Rolls Out Lenacapavir to Prevent HIV Read Post »
Health TidingsNICE Endorses AbbVie’s Elahere as First New NHS Therapy in Over 20 Years ... NICE Endorses AbbVie’s Elahere as First New NHS Therapy in Over 20 Years ... Read Post »
Health TidingsMHRA Authorizes Aujemflu for Influenza Prevention in Adults 50+ MHRA Authorizes Aujemflu for Influenza Prevention in Adults 50+ Read Post »
Health TidingsADC Plans FDA Filing After Positive LOTIS-5 Results for ZYNLONTA ADC Plans FDA Filing After Positive LOTIS-5 Results for ZYNLONTA Read Post »
Health TidingsOtsuka Shows VOYXACT Slowed Kidney Function Decline in IgA Nephropathy Otsuka Shows VOYXACT Slowed Kidney Function Decline in IgA Nephropathy Read Post »
Health TidingsIV Ketamine Outperformed Esketamine in NRx’s Real-World Depression St... IV Ketamine Outperformed Esketamine in NRx’s Real-World Depression St... Read Post »
GenericsLupin and Alembic Secure FDA Approvals, Expanding Indian Pharma’s U.S. Fo... Lupin and Alembic Secure FDA Approvals, Expanding Indian Pharma’s U.S. Fo... Read Post »
Health TidingsFDA Issues Complete Response Letter for Xspray’s Nilopki NDA FDA Issues Complete Response Letter for Xspray’s Nilopki NDA Read Post »
GenericsTeva Enters Ophthalmology With European Launch of AHZANTIVE Teva Enters Ophthalmology With European Launch of AHZANTIVE Read Post »
Health TidingsUCB and Biogen Present New Phase 3 Dapirolizumab Pegol Results in SLE UCB and Biogen Present New Phase 3 Dapirolizumab Pegol Results in SLE Read Post »
Health TidingsFDA Grants Breakthrough Therapy Designation to Biogen’s Salanersen for SM... FDA Grants Breakthrough Therapy Designation to Biogen’s Salanersen for SM... Read Post »
Health TidingsFDA Accepts Pharming’s Pediatric sNDA for Joenja® in APDS FDA Accepts Pharming’s Pediatric sNDA for Joenja® in APDS Read Post »
Health TidingsTerremoto Advances TER-2013 With FDA Fast Track Designation Terremoto Advances TER-2013 With FDA Fast Track Designation Read Post »
Health TidingsCingulate’s ADHD Drug CTx-1301 Hit with FDA Complete Response Letter Cingulate’s ADHD Drug CTx-1301 Hit with FDA Complete Response Letter Read Post »
GenericsApotex Launches Lower-Cost Sitagliptin Therapies for Type 2 Diabetes Apotex Launches Lower-Cost Sitagliptin Therapies for Type 2 Diabetes Read Post »
Health Tidings Mergers & AcquisitionsIDEAYA and Roche Advance PRMT5 and Pan-RAS Inhibitors in Pancreatic Cancer IDEAYA and Roche Advance PRMT5 and Pan-RAS Inhibitors in Pancreatic Cancer Read Post »
Health Tidings Mergers & AcquisitionsAscidian Secures Up to $1.9 Billion in Lilly Kidney Disease Partnership Ascidian Secures Up to $1.9 Billion in Lilly Kidney Disease Partnership Read Post »
Health TidingsKura Reports Early Success for Darlifarnib in KRAS-Mutant Solid Tumors Kura Reports Early Success for Darlifarnib in KRAS-Mutant Solid Tumors Read Post »
Health TidingsKyverna Reports Sustained Clinical Benefit With miv-cel in Refractory RA Kyverna Reports Sustained Clinical Benefit With miv-cel in Refractory RA Read Post »
Health Tidings Mergers & AcquisitionsCytomX Secures Expanded Regeneron Partnership Worth Up to $4 Billion CytomX Secures Expanded Regeneron Partnership Worth Up to $4 Billion Read Post »
GenericsLupin and Natco Secure FDA Approval for Eribulin Mesylate Injection Lupin and Natco Secure FDA Approval for Eribulin Mesylate Injection Read Post »
Health TidingsMannKind Advances Inhaled Nintedanib into Phase 2 Trial for IPF MannKind Advances Inhaled Nintedanib into Phase 2 Trial for IPF Read Post »
Health TidingsPrimary Endpoint Miss Leads Praxis to Reassess Vormatrigine Strategy Primary Endpoint Miss Leads Praxis to Reassess Vormatrigine Strategy Read Post »
Health TidingsVera’s Atacicept Heads Toward Full Approval After FDA Aligns on Earli... Vera’s Atacicept Heads Toward Full Approval After FDA Aligns on Earli... Read Post »
Health TidingsLantern Reports Durable LP-300 Responses in EGFR L858R Lung Cancer Lantern Reports Durable LP-300 Responses in EGFR L858R Lung Cancer Read Post »
Health TidingsRoche’s Giredestrant Wins FDA Priority Review for Early Breast Cancer Roche’s Giredestrant Wins FDA Priority Review for Early Breast Cancer Read Post »
Health Tidings Mergers & AcquisitionsCEPI Backs Moderna’s Bundibugyo Ebola Vaccine with $50 Million CEPI Backs Moderna’s Bundibugyo Ebola Vaccine with $50 Million Read Post »
Health TidingsFDA Accepts Vertex’s Povetacicept After Strong Phase 3 IgAN Results FDA Accepts Vertex’s Povetacicept After Strong Phase 3 IgAN Results Read Post »
Health Tidings Mergers & AcquisitionsServier Acquires Edgewise Muscular Dystrophy Business for Up to $2.65 Billi... Servier Acquires Edgewise Muscular Dystrophy Business for Up to $2.65 Billi... Read Post »
Health TidingsUCB, Biogen Report Positive PHOENYCS GO Results in SLE UCB, Biogen Report Positive PHOENYCS GO Results in SLE Read Post »
Health TidingsPfizer’s BRAFTOVI Cuts Progression Risk by 56% in BRAF V600E mCRC Pfizer’s BRAFTOVI Cuts Progression Risk by 56% in BRAF V600E mCRC Read Post »
Health TidingsRevMed’s Daraxonrasib Cuts Death Risk by 60% in PDAC RevMed’s Daraxonrasib Cuts Death Risk by 60% in PDAC Read Post »
Health TidingsIndustry Perspective: What Wockhardt’s ZAYNICH FDA Approval Means for Pat... Industry Perspective: What Wockhardt’s ZAYNICH FDA Approval Means for Pat... Read Post »
Health TidingsOtsuka Reports Positive Phase 3 Results of Centanafadine in Adult ADHD Ahea... Otsuka Reports Positive Phase 3 Results of Centanafadine in Adult ADHD Ahea... Read Post »
Health TidingsEU Expands Comirnaty Authorization for Children Under 5 EU Expands Comirnaty Authorization for Children Under 5 Read Post »
Health TidingsMHRA Approves Sanofi’s Rilzabrutinib for Adults with Chronic ITP MHRA Approves Sanofi’s Rilzabrutinib for Adults with Chronic ITP Read Post »
Health TidingsWHO Endorses Regeneron’s Maftivimab for Bundibugyo Ebola Trials WHO Endorses Regeneron’s Maftivimab for Bundibugyo Ebola Trials Read Post »
Health TidingsBMS’s Mezigdomide Hits Phase 3 Goal in Relapsed Myeloma BMS’s Mezigdomide Hits Phase 3 Goal in Relapsed Myeloma Read Post »
Health TidingsMerck Advances Calderasib With FDA Breakthrough Therapy Designation in Lung... Merck Advances Calderasib With FDA Breakthrough Therapy Designation in Lung... Read Post »
Health TidingsPhase 2b Failure Ends Agios’ Tebapivat Program in Lower-Risk MDS Phase 2b Failure Ends Agios’ Tebapivat Program in Lower-Risk MDS Read Post »
Health TidingsReplimune Aligns with FDA on RP1 Resubmission Path in Advanced Melanoma Replimune Aligns with FDA on RP1 Resubmission Path in Advanced Melanoma Read Post »
Health TidingsFDA Extends Review of Beren’s Adrabetadex NDA for Infantile-Onset NPC FDA Extends Review of Beren’s Adrabetadex NDA for Infantile-Onset NPC Read Post »
Health Tidings Mergers & AcquisitionsPfizer and Innovent Strike Oncology Deal Worth Up to $10.5 Billion Pfizer and Innovent Strike Oncology Deal Worth Up to $10.5 Billion Read Post »
Health TidingsLilly Secures Nationwide PBM Coverage for Obesity Portfolio Lilly Secures Nationwide PBM Coverage for Obesity Portfolio Read Post »
Health TidingsFDA Starts Priority Review of Venglustat for Neurological Gaucher Disease FDA Starts Priority Review of Venglustat for Neurological Gaucher Disease Read Post »
Health TidingsFDA Grants Priority Review to Cogent’s Bezuclastinib in Second-Line GIST FDA Grants Priority Review to Cogent’s Bezuclastinib in Second-Line GIST Read Post »
